Vemurafenib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB08881 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 28 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | HIV infectious disease | KG + DL |
| 2 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | KG + DL |
| 3 | feline acquired immunodeficiency syndrome | KG + DL |
| 4 | simian immunodeficiency virus infection | KG + DL |
| 5 | acute intermittent porphyria | KG + DL |
| 6 | collagenopathy | KG + DL |
| 7 | paratenonitis | KG + DL |
| 8 | female breast carcinoma | KG + DL |
| 9 | calcific tendinitis | KG + DL |
| 10 | lymphocytic hypereosinophilic syndrome | KG + DL |
| 11 | Plasmodium falciparum malaria | KG + DL |
| 12 | homozygous familial hypercholesterolemia | KG + DL |
| 13 | gout | KG + DL |
| 14 | obsolete familial combined hyperlipidemia | KG + DL |
| 15 | dermatofibrosarcoma protuberans | KG + DL |
| 16 | myositis | KG + DL |
| 17 | headache disorder | KG + DL |
| 18 | rheumatoid arthritis | KG + DL |
| 19 | trigeminal autonomic cephalalgia | KG + DL |
| 20 | arteriosclerosis disorder | KG + DL |
| 21 | AIDS | KG + DL |
| 22 | generalized atherosclerosis | KG + DL |
| 23 | cerebral atherosclerosis | KG + DL |
| 24 | hypereosinophilic syndrome | KG + DL |
| 25 | porphyria | KG + DL |
| 26 | Smouldering systemic mastocytosis | KG + DL |
| 27 | multiple sclerosis | KG + DL |
| 28 | primary hereditary glaucoma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.